SEPSIS THERAPY TRIALS - CONTINUED DISAPPOINTMENT OR REASON FOR HOPE

被引：42

作者：

ABRAHAM, E

RAFFIN, TA

机构：

[1] STANFORD UNIV, MED CTR, DIV PULM & CRIT CARE MED, STANFORD, CA 94305 USA

[2] UNIV COLORADO, HLTH SCI CTR, DIV PULM SCI & CRIT CARE MED, CRIT CARE MED SECT, DENVER, CO USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1994年 / 271卷 / 23期

关键词：

D O I：

10.1001/jama.271.23.1876

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1876 / 1878

页数：3

共 11 条

[1] PROGNOSTIC VALUES OF TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, INTERFERON-ALPHA, AND INTERFERON-GAMMA IN THE SERUM OF PATIENTS WITH SEPTIC SHOCK [J].

CALANDRA, T ;

BAUMGARTNER, JD ;

GRAU, GE ;

WU, MM ;

LAMBERT, PH ;

SCHELLEKENS, J ;

VERHOEF, J ;

GLAUSER, MP .

JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :982-987

[2] INTERLEUKIN-1 RECEPTOR BLOCKADE IMPROVES SURVIVAL AND HEMODYNAMIC PERFORMANCE IN ESCHERICHIA-COLI SEPTIC SHOCK, BUT FAILS TO ALTER HOST RESPONSES TO SUBLETHAL ENDOTOXEMIA [J].

FISCHER, E ;

MARANO, MA ;

VANZEE, KJ ;

ROCK, CS ;

HAWES, AS ;

THOMPSON, WA ;

DEFORGE, L ;

KENNEY, JS ;

REMICK, DG ;

BLOEDOW, DC ;

THOMPSON, RC ;

LOWRY, SF ;

MOLDAWER, LL .

JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (05) :1551-1557

[3] RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

FISHER, CJ ;

DHAINAUT, JFA ;

OPAL, SM ;

PRIBBLE, JP ;

BALK, RA ;

SLOTMAN, GJ ;

IBERTI, TJ ;

RACKOW, EC ;

SHAPIRO, MJ ;

GREENMAN, RL ;

REINES, HD ;

SHELLY, MP ;

THOMPSON, BW ;

LABRECQUE, JF ;

CATALANO, MA ;

KNAUS, WA ;

SADOFF, JC ;

ASTIZ, M ;

CARPATI, C ;

BONE, RC ;

FREIDMAN, B ;

MURE, AJ ;

BRATHWAITE, C ;

SHAPIRO, E ;

MELHORN, L ;

TAYLOR, R ;

KEEGAN, M ;

OBRIEN, J ;

SCHEIN, R ;

PENA, M ;

WASSERLOUF, M ;

OROPELLO, J ;

BENJAMIN, E ;

DELGUIDICE, R ;

EMMANUEL, G ;

LIE, T ;

ANDERSON, L ;

MARSHALL, J ;

DEMAJO, W ;

ROTSTEIN, O ;

FOSTER, D ;

ABRAHAM, E ;

MIDDLETON, H ;

PERRY, C ;

LEVY, H ;

FRY, DE ;

SIMPSON, SQ ;

CROWELL, RE ;

NEIDHART, M ;

STEVENS, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843

[4] INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL [J].

FISHER, CJ ;

SLOTMAN, GJ ;

OPAL, SM ;

PRIBBLE, JP ;

BONE, RC ;

EMMANUEL, G ;

NG, D ;

BLOEDOW, DC ;

CATALANO, MA ;

FRIEDMAN, B ;

MURE, A ;

SHAPIRO, E .

CRITICAL CARE MEDICINE, 1994, 22 (01) :12-21

[5] A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS [J].

GREENMAN, RL ;

SCHEIN, RMH ;

MARTIN, MA ;

WENZEL, RP ;

MACINTYRE, NR ;

EMMANUEL, G ;

CHMEL, H ;

KOHLER, RB ;

MCCARTHY, M ;

PLOUFFE, J ;

RUSSELL, JA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08) :1097-1102

[6] THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDY DESIGN BASED ON SURVIVAL ANALYSIS [J].

KNAUS, WA ;

HARRELL, FE ;

FISHER, CJ ;

WAGNER, DP ;

OPAL, SM ;

SADOFF, JC ;

DRAPER, EA ;

WALAWANDER, CA ;

CONBOY, K ;

GRASELA, TH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (10) :1233-1241

[7] INTERLEUKIN-1 RECEPTOR ANTAGONIST REDUCES MORTALITY FROM ENDOTOXIN-SHOCK [J].

OHLSSON, K ;

BJORK, P ;

BERGENFELDT, M ;

HAGEMAN, R ;

THOMPSON, RC .

NATURE, 1990, 348 (6301) :550-552

[8] INTERLEUKIN-1 INDUCES A SHOCK-LIKE STATE IN RABBITS - SYNERGISM WITH TUMOR NECROSIS FACTOR AND THE EFFECT OF CYCLOOXYGENASE INHIBITION [J].

OKUSAWA, S ;

GELFAND, JA ;

IKEJIMA, T ;

CONNOLLY, RJ ;

DINARELLO, CA .

JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (04) :1162-1172

[9]

TENAILLON A, 1993, AM REV RESPIR DIS, V147, pA97

[10]

WHERRY J, 1993, CHEST, V104, P35

← 1 2 →